• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

By: ACCESS Newswire
June 20, 2025 at 13:15 PM EDT

PITTSBURGH, PA / ACCESS Newswire / June 20, 2025 / Law Office of Alfred G. Yates Jr. PC announces investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. - Immunovant's controlling stockholder - in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing price.

If you are currently an Immunovant investor and would like to learn more, you can provide your information here: https://yatesclassactionlaw.com/

Contact attorney Alfred G. Yates, Jr. by calling (412) 391-5164 or via e-mail at yateslaw@aol.com.

THE COMPANY: Immunovant is a clinical-stage immunology company. In December 2019, a blank check company under the name Health Sciences Acquisitions Corporation ("HSAC") merged with Immunovant Sciences Ltd., which was a majority-owned subsidiary of Roivant. Subsequent to the merger, HSAC changed its name to Immunovant, Inc. At all times since the merger, Roivant has controlled a majority of Immunovant's stock, holding between 54.6% and 73.8% of Immunovant's shares.

THE TRANSACTION: On January 13, 2025, Immunovant announced, prior to the start of trading, that it had entered into a share purchase agreement with Roivant. Pursuant to the agreement, Immunovant sold 16,845,010 shares of the company's common stock to Roivant via a private placement for $20.00 per share, a $3.48 per share discount to the prior trading day's closing price. The last time Immunovant's share price had closed as low as $20.00 per share was in August 2023 - nearly a year and a half before the private placement. This $3.48 per share discount, when multiplied by the 16,845,010 shares Roivant received pursuant to the agreement, equates to a benefit to Roivant of nearly $60 million at the expense of Immunovant and its shareholders.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Contacts

Alfred G. Yates Jr., Esquire
Law Office of Alfred G. Yates Jr. PC
(412) 391-5164
1-844-391-5164
yateslaw@aol.com
yatesclassactionlaw.com

SOURCE: Law Office of Alfred G. Yates, Jr., P.C.



View the original press release on ACCESS Newswire

More News

View More
FICO’s Big Dip Could Be the Best Buying Chance of the Year
October 13, 2025
Via MarketBeat
Tickers EFX FICO
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
October 13, 2025
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
October 13, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
October 13, 2025
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
October 13, 2025
Via MarketBeat
Tickers DAL
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap